Related Experiment Video
Updated: Jan 31, 2026

Transient Treatment of Human Pluripotent Stem Cells with DMSO to Promote Differentiation
Published on: July 17, 2019
Regulatory considerations for pluripotent stem cell therapies
1Carpenter Group Consulting, Seattle, WA, United States.
Abstract:
The development of pluripotent stem cell (PSC) therapies is rapidly advancing, and a number of PSC-derived cell products are currently being tested in clinical trials. The biological complexity of these therapies results in specific challenges in complying with regulatory guidelines. This includes the choice of starting material, reproducible and consistent manufacturing, and preclinical safety and efficacy assessment of the PSC-derived product. This review discusses current US cell therapy regulations and strategies for compliance with these regulations when developing PSC-derived products.
Related Concept Videos
Induced Pluripotent Stem Cells
Induced Pluripotent Stem Cells
Somatic...
Stem Cell Therapy for Tissue Regeneration
Types of Stem Cells used in Stem Cell Therapy
The two main cell...
Embryonic Stem Cells
Cis-regulatory Sequences
Cis-regulatory Sequences

